Genentech Reveals New Phase III Clinical Trial Data
The company presented findings on three neurological drugs at the MSToronto2026 conference in Toronto.
Updated on Oct. 21, 2026 in Stroke
Live Poll
Do you trust that new medical trial data will lead to better health outcomes for patients?
Genentech released positive Phase III clinical trial results for its drug fenebrutinib, as well as updated data for Ocrevus and Enspryng. These findings were presented at the MSToronto2026 meeting held from October 21-23, 2026.
Why it matters
The study data highlights potential advancements in treating both acute and chronic neuroinflammation by targeting B cells and microglia. These results provide new insights into managing disability progression and relapse rates for patients with multiple sclerosis.
Fenebrutinib reduced slowly expanding lesions by up to 30% and paramagnetic rim lesions by 62% in patients with relapsing multiple sclerosis. Furthermore, 75% of treated patients showed no evidence of disease activity after nearly two years.
The players
Genentech
A biotechnology company headquartered in South San Francisco that focuses on developing medicines for serious diseases.
The details
Fenebrutinib, a Bruton's tyrosine kinase inhibitor that crosses the blood-brain barrier, showed a 23% reduction in total annual brain volume loss. Additional data indicated that 90% of children aged 10-17 remained relapse-free on Ocrevus, while 53% of patients over age 55 showed no disability progression.
Timeline
The MSToronto2026 meeting took place from October 21-23, 2026.
An FDA decision regarding Enspryng for MOGAD is expected in January 2027.
Health Landscape
The clinical trial results presented at the MSToronto2026 meeting mark a significant update in the landscape of neuroimmunology research. These findings reflect an evolution in how pharmaceutical companies address chronic neuroinflammation compared to legacy treatment approaches.
These results offer potential new therapeutic avenues for patients dealing with relapsing multiple sclerosis and MOGAD. Patients should consult their healthcare providers to discuss how these emerging treatments may eventually impact their personal care and disease management plans.
The takeaway
These findings underscore the importance of targeted therapies in reducing long-term brain volume loss and relapse rates. Patients are encouraged to track the upcoming regulatory decisions that may expand access to these specialized neurological treatments.
What happens next
Genentech expects an FDA decision on the use of Enspryng for MOGAD treatment in January 2027.
Further reading
For more information on similar medical research, visit our Stroke section.
More information
For further corporate details, visit the Genentech company information page.
Live Poll
Do you trust that new medical trial data will lead to better health outcomes for patients?
